Kissei Pharmaceutical Co., Ltd. (4547) Press Release
Notice Concerning Status of Acquisition of Treasury Shares
Earlier from Kissei Pharmaceutical
- Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
- Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
- Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
- Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments